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Axonal excitability and conduction alterations caused by 
levobupivacaine in rat
In this study, eff ects of the long-acting amide-type local anes-
thetic levobupivacaine on axonal conduction and excitability pa-
rameters of the rat sciatic nerve were thoroughly examined both 
in vitro and in vivo. In order to deduce its eff ects on isolated nerve 
conduction, compound nerve action potential (CNAP) recordings 
were performed using the suction method over sciatic nerves of 
Wistar rats before and aft er administration of 0.05 % (1.7 mmol 
L–1) levobupivacaine. Levobupivacaine caused complete CNAP 
area and amplitude depression by blocking conduction in a time-
dependent manner.
To assess the infl uence of levobupivacaine on in vivo excitability 
properties, threshold-tracking (TT) protocols were performed at 
sciatic nerves of rats injected with perineural 0.05 % (1.7 mmol 
L–1) levobupivacaine or vehicle alone. Charge-duration TT results 
revealed that levobupivacaine increases the rheobase and de-
creases the strength-duration time constant, suggesting interfer-
ence of the anesthetic with the opening of Na+ channels. Twenty 
and 40 % threshold electrotonus curves were found for both 
groups to follow the same paths, suggesting no signifi cant eff ect 
of levobupivacaine on K+ channels for either the fastest or rela-
tively slow conducting fi bers. Current-threshold relationship re-
sults revealed no signifi cant eff ect on axonal rectifying channels. 
However, according to the results of the recovery cycle protocol 
yielding the patt ern of excitability changes following the im-
pulse, potential deviation was found in the recovery characteris-
tics of Na+ channels from the absolute refractory period. Conse-
quently, conduction blockage caused by levobupivacaine may not 
be due to the passive (capacitive) properties of axon or the con-
ductance of potassium channels but to the decrease in sodium 
channel conductance.
Keywords:  levobupivacaine, nerve conduction, excitability, 
threshold electrotonus
Levobupivacaine is a long-acting amide-type local anesthetic that interferes with 
voltage-gatedion channels. The anesthetic and/or analgesic eff ects of levobupivacaine have 
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dose, in many comparative studies, including those of epidural, peripheral nerve blockage, 
local infi ltration and peribulbar administration (1). The sensory block due to levobupiva-
caine is longer than that of bupivacaine when used on peripheral nerves, not imposing any 
cardiovascular or CNS toxicity because of its enantio selectivity. On the contrary, bupiva-
caine has been shown to produce aQTc interval prolongation on ECG and overall depres-
sion of EEG signals. Levobupivacaine is a local anesthetic widely known for its blocking 
eff ect on Na+ channels, but in recent studies it has been shown to aff ect K+, Ca2+, transient 
receptor potential vanilloid 1 (TRPV1) channels and N-methyl-D-aspartate (NMDA), 
α-amino-3-hydroxy-5-methyl-4-izoxazolepropionic acid (AMPA), and GTP-binding pro-
tein coupling receptors (2). Combined eff ects of levobupivacaine on these ion channels and 
receptors could result in complicated changes in peripheral nerve conduction and excita-
bility.
Since the ingenious works of Gasser and co-workers in the late 1930s (3), methods 
depending on the compound nerve action potential (CNAP) recording have been used as 
a useful means for the evaluation of nerves both for the purpose of research and clinical 
diagnosis. To get detailed information on the individual activity of nerve fi ber groups, 
CNAP recording from isolated nerves is still considered as the primary method of choice 
(4). However, thanks to the threshold tracking (TT) method developed by Bostock et al. (5) 
in the last decade, more parameters about nerve excitability could be acquired reliably. 
Since the excitability of an axon could be defi ned as the current required to yield a spe-
cifi c level of response, excitability can be indirectly measured over the applied amount of 
electrical current. Depolarization of an axon increases its excitability and there by de-
creases the strength of threshold current needed to cause excitation; hence, a weaker cur-
rent would be needed to produce the same magnitude of response, and vice versa. On the 
other hand, hyperpolarization of the axon increases the amount of current needed to pro-
duce a comparable response. In this method, a given response amplitude of the target 
compound muscle action potential (CMAP) or compound nerve action potential (CNAP), 
consisting of the sum of individual activities of muscle or nerve fi bers, is preset. The 
threshold current strength is then automatically adjusted to elicit this constant target re-
sponse. These automatically driven patt erns of “percent change threshold” are taken to be 
an accurate representation of axonal excitability under the point of stimulation (6).
A myelinated axon has ion channels, pumps and exchangers responsible for deter-
mining axonal excitability. In the node of Ranvier, transient Na+ channels (Nat) are dense-
ly clustered together with persistent Na+ channels (Nap) and slow K+ channels (Ks), which 
as a whole contribute to the excitability and resting membrane potential. In addition to Ks, 
the internodal region of the axon includes fast K+ channels (Kf) scatt ered densely, acting to 
limit re-excitation of the node just aft er an action potential, and hyperpolarization-activat-
ed (inward rectifying) K+ channels (6, 7).
Levobupivacaine is the frequently preferred local anesthetic, which has previously 
been shown to be capable of blocking rat sciatic nerve conduction (8). Its eff ects on nerve 
conduction and excitability parameters have been extensively studied, using traditional 
CNAP recording and TT methods, for the appropriate dose of perineural administration. 
TT is a relatively new method that provides information about the changes in ion channel 
activity; it enables on going assessment for clinical validation of several studies. Its main 
advantage over other methods is that it provides, non-invasively, a means for in vivo mea-
surement of ion channel activity (6). The aim of the present study was to investigate in 
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detail the eff ects of levobupivacaine on nerve excitability in order to enlighten the changes 
in ionic channel activity. In addition, the conduction parameters acquired from the iso-
lated nerve were evaluated for the conduction blockage eff ect of anesthetic agents by 
means of the traditional CNAP recording method.
EXPERIMENTAL
Animals
The experiments were carried out on 24 male adult Wistar albino rats, weighing 250-
350 g, purchased from KONUDAM (N. E. University Experimental Medicine and Applica-
tion Center, Konya, Turkey). All experimental procedures on animals were carried out in 
accordance with the ARRIVE guidelines and instructions of the Meram Medical Faculty 
Experimental Ethics Committ ee (N. E. University, Konya, Turkey). Aft er birth, rats were 
housed fi ve per cage at ambient temperature and humidity under a 12/12 h light/dark cycle. 
All animals received food and water ad libitum. Rats were maintained without any signs 
of neuro behavioral impairment throughout the experiments. Animals were separated 
into two groups, i.e., 8 rats for in vitro CNAP recordings from isolated sciatic nerves and 16 
rats for in vivo multiple excitability measurements.
CNAP recording
In order to perform CNAP recording, right sciatic nerves of the fi rst group of rats were 
dissected at the hind paw aft er being sacrifi ced by cervical dislocation under deep anes-
thesia (intraperitoneal injection of 90 mg kg–1 ketamine and 10 mg kg–1 xylazine combina-
tion). Nerves were then rapidly transferred to the recording chamber super fused with 
modifi ed Krebs solution (composed of, in mmol L–1: NaCl 119, KCl 4.8, CaCl2 1.8, MgSO4 
1.2, KH2PO4 1.2, NaHCO3 20, and glucose 10, pH 7.4, and gassed with a mixture of 95 % O2 
and 5 % CO2) at a constant rate of 5 mL min–1 at constant temperature (37 ± 0.5 °C). Tem-
perature was maintained using a heat jacket in the course of recording experiments. Stim-
uli were given with a stimulator (Model S88K, Grass Instruments Co., USA) at proximal 
ends of the nerve trunk via a stimulus isolation unit (Model SIU5, Grass Instruments Co.). 
Square-wave pulses of supramaximal intensity (100 μs duration and 1 Hz frequency) were 
used for nerve stimulation. CNAP recordings were performed via a suction electrode 
placed at the tibial branch of the isolated nerve trunk. Amplifi ed CNAP signals (Model 
CP511 AC amplifi er, Grass Instruments Co.) were digitized using an A/D converter card 
(Model PCL 1710, Advantech, Taiwan) at 40 KSPS (kilosamples s–1) using the open-source 
CNAP recording soft ware RETICAP (htt p://icon.unrlabs.org/projects/reticap/) produced in 
our laboratory and stored on hard disk for further analysis. Initial CNAP recordings with-
out levobupivacaine were considered as the baseline (0th-min signals) and referred to as 
CNAP0. Aft er completing these initial recordings, by substituting the solution with an-
other Krebs solution containing 0.05 % (1.7 mmol L–1) levobupivacaine, CNAP recordings 
were performed every 5 min for 30 min until CNAPs vanished completely. These record-
ings aft er the 5th, 10th, 15th, 20th and 25th-min are, respectively, referred to as CNAP5, 
CNAP10, CNAP15, CNAP20 and CNAP25 throughout the text.
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Multiple excitability measurements
Multiple excitability measurement tests were performed on 16 rats divided into two 
groups having equal numbers of animals (n = 8). Rats in the fi rst group, labeled LEV, were 
unilaterally administered a percutaneous injection of 0.5 mL of levobupivacaine (0.05 %, 
1.7 mmol L–1) into the perineural space below the clear fascia covering the nerve itself, 
proximal to the bifurcation of the sciatic nerve. The second group (CON) served as a control 
and received 0.5 mL of saline (0.9 % NaCl), which served as a vehicle for levobupivacaine. 
Before perineural injection, rats were anaesthetized with an intraperitoneal injection of 90 
mg kg–1 ketamine and 10 mg kg–1 xylazine combination to produce deep anesthesia. To 
maintain the level of anesthesia, supplementary doses were administered as required.
To conduct TT experimental protocols, thirty minutes aft er the perineural injection of 
levobupivacaine, the lower back regions of rats were shaved and placed prone on a heated 
table (MAY RTC9404-A Animal Rectal Temperature Controller, Commat Ltd., Turkey), 
which was controlled by a rectal thermistor probe to keep the body temperature at 37 °C. 
A stainless steel stimulating surface electrode pair was placed on the sciatic nerve, and Ag/
AgCl recording surface electrodes were positioned properly on the gastrocnemius muscle 
groups innervated by these nerves, very close to the point of perineural injection. The ring 
electrode serving as ground was att ached to the tail. Compound muscle action potentials 
(CMAPs) were amplifi ed and fi ltered (1 Hz to 3 kHz, Warner Instrument DP311 Amplifi er, 
USA) and line interference was removed using an online noise eliminator (HumBug 50/60 
Hz Noise Eliminator, Digitimer Co., UK). The resultant signals were then digitized using 
a computer having an analog-digital converter at a sampling rate of 10 KSPS (National 
Instrument NI USB-6251 M series DAQ Device, USA). Stimulation was controlled by 
QTRACS soft ware connected to a data acquisition unit and a stimulator (DS5 type, Digi-
timer Co., UK). Fig. 1 illustrates the placement of stimulating and recording electrode pairs 
and the system used for the TT experiment.
In order to assess multiple excitability parameters, standard TT methods were applied 
(9). Experimental procedure was performed using the soft ware in which multiple excita-
bility protocol TRONDNF of QTRACS was implemented (H. Bostock, UCL Institute of 
Neurology, London, UK). Methodology and details of the equipment employed in this 
procedure were previously described elsewhere (6, 9–12). Briefl y, the fi rst step in our ex-
periments was to obtain the CMAP of maximal amplitude by gradually increasing the 
stimulus strength by 2 %-steps. TRONDNF protocol mainly depends on the tracking of the 
current required to generate a target response of 40 % of maximal CMAP amplitude. The 
stimulus-response, strength-duration relationship, threshold electrotonus, current-thres-
hold relationship and recovery cycle parameters were investigated during the multiple 
excitability testing procedure.
In the course of electrotonus, excitability was tested during and aft er polarizing cur-
rents of 100 ms duration, for both ±20 and ±40 % of the control threshold current. For the 
current (mA)-threshold (V) relationship, excitability was tested in the period following 
200-ms lasting current pulses for the range of +50 to –100 % of the control threshold current 
by steps of 10 %. For the recovery cycle, excitability was tested for 18 intervals from 1.5 to 
200 ms following a supramaximal conditioning stimulus.
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Data analysis
CNAP recordings. – Calculations were conducted on the isolated nerve for two separate 
conduction velocity (m s–1) values, representing the fastest and the relatively slow conduct-
ing groups. The fi rst (CVinit) was derived using latency1 (Δtonset), i.e., the time delay be-
tween the instant of stimulus delivery and the associated CNAP onset, while the second 
(CVpeak) was computed for latency 2 (Δtpeak), the time delay between the stimulus delivery 
instant and the associated CNAP reaching its maximum value. The distance of the travel-
ing wave used in calculations was 30 mm. The amplitude of CNAPs (mV) and the areas 
under CNAPs (mV.ms) were also measured.
Multiple excitability tests. – Recordings obtained via the TRONDNF protocol were ana-
lyzed and plott ed using the QTRACP program, which performs an automated analysis of 
multiple excitability parameters. Analyses of excitability measurements were mainly done 
using data obtained from the stimulus-response relationship, strength-duration relation-
ship, threshold electrotonus, current-threshold relationship and recovery cycle protocols, 
which are the sub-protocols of TRONDNF, as previously described elsewhere (8).
Statistics. – Unless otherwise specifi ed, comparisons for time dependent eff ects of le-
vobupivacaine were made using the one-way analysis of variance (ANOVA), followed by 
Duncan’s post-hoc test for multiple comparisons where ANOVA yielded a signifi cant result. 
Student’s t-test was used to determine whether levobupivacaine did or did not aff ect excita-
bility parameters. Reliability of our results was tested using Cohen’s d eff ect size calcula-
tion method and according to the obtained d results for all parameters, sample size was 
Fig. 1. Schematic diagram of the placement of stimulating and recording electrodes, and the system 
used for in vivo TT recordings. 
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found to be suffi  cient (13). Statistical analyses were performed using the GraphPad Prism 
5 soft ware, where p-values of < 0.05 were regarded as signifi cant. Data were presented as 
mean ± SEM throughout the text.
RESULTS AND DISCUSSION
CNAP parameters
The CNAP depression eff ect of levobupivacaine on isolated rat sciatic nerves is given 
in Fig. 2. This sample CNAP recording demonstrates that levobupivacaine administration 
suppresses the CNAPs recorded from isolated nerves in a time-dependent manner, com-
pletely abolishing the CNAPs within 25 min. This eff ect was found to be reversible. 
Changes in the area under CNAP, CNAP amplitude, conduction velocities of the fastest 
(CVinit) and medium velocity (CVpeak) fi ber groups were computed using CNAP data at 
5-min intervals aft er the administration (t = 0) of levobupivacaine (Fig. 3).
Multiple excitability measurements
A representative CMAP recording from the gastrocnemius muscle (as in Fig. 1) 
demon strating the presence and absence of levobupivacaine is given in Fig. 4. Excitability 
parameters of the rat sciatic nerve associated with CMAPs are summarized for CON 
and LEV groups in Table I.
Fig. 2. Representative CNAP samples recorded in vitro from isolated rat sciatic nerves. CNAP curves 
belong to time sequences starting with the initial recording (CNAP0) and then 5, 10, 15, 20, 25 min 












S. Tuncer et al.: Axonal excitability and conduction alterations caused by levobupivacaine in rat, Acta Pharm. 67 (2017) 293–307.
 
Fig. 3. Time dependent in vitro eff ect of levobupivacaine (1.7 mmol L–1) and aft er a 30-minute washout 
period on diff erent CNAP parameters: a) area, b) amplitude, c) conduction velocity of the fastest fi bers 
(CVinit) and d) conduction velocity of medium fi bers (CVpeak). The values are given as mean ± SEM, 
n = 8.
Fig. 4. A representative CMAP recording from the gastrocnemius muscle (as shown in Fig. 1), demon-
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Table I. Multiple excitability parameters of the rat sciatic nerve for CON and LEV groups
Excitability measure CONa LEVa
Stimulus-response relationship
Stimulus for 50 % max response (mA) 2.56 ± 0.23 3.39 ± 0.22*
Peak CMAP (mV) 34.68 ± 1.39 34.44 ± 2.01
Strength-duration relationship
Strength-duration time constant (ms) 0.27 ± 0.01 0.21 ± 0.02*
Rheobase (mA) 1.94 ± 0.18 2.70 ± 0.19*
Latency (ms) 3.34 ± 0.06 3.66 ± 0.07
Threshold electrotonus
TEd40 (10–20 ms) 39.92 ± 0.68 37.58 ± 2.01
TEd40 (peak) 40.21 ± 0.54 38.85 ± 1.73
TEd40 (90–100 ms) 28.10 ± 0.80 25.73 ± 2.20
TEd40 (undershoot) –11.13 ± 0.67 –12.59 ± 1.14
TEd20 (peak) 20.78 ± 0.23 19.57 ± 0.10
TEh40 (10–20 ms) –45.53 ± 0.72 –42.79 ± 1.79
TEh40 (20–40 ms) –49.30 ± 1.22 –45.28 ± 2.43
TEh40 (90–100 ms) –50.82 ± 1.59 –46.92 ± 2.75
TEh40 (overshoot) 4.35 ± 0.55 6.56 ± 0.63
Current threshold relationship curve
Resting slope of the curve 1.14 ± 0.03 1.47 ± 0.29
Minimum slope of the curve 0.39 ± 0.01 0.38 ± 0.02
Hyperpolarizing slope of the curve 0.39 ± 0.01 0.38 ± 0.02
Recovery cycle
Refractoriness at 2.5 ms (%) 37.74 ± 4.30 65.90 ± 5.20b
Peak super-excitability (%) –6.90 ± 2.96 –6.71 ± 2.56
Peak late sub-excitability (%) 2.87 ± 0.50 2.86 ± 0.91
a Values are given as mean ± SEM, n = 8.
b Statistically signifi cant diff erence vs. CON: p < 0.05.
Comparison of the stimulus response relation ship of LEV and CON is given in Fig. 
5a. A signifi cant increase, compared to CON, was found in stimulus current strength (in 
mA), yielding 50 % of maximal response (Fig. 5b).
Curves associated with strength-duration properties of CON and LEV groups are 
given in Fig. 6a. According to Weiss’s law, as the duration of a test stimulus is increased, 
current strength required to excite a single nerve fi ber or bundle decreases exponentially, 
eventually fl att ening out a symptotically for long stimulus durations to reach a value 
called rheobase (5). The excitability parameters, strength-duration time constant (SDTC) 
and rheobase values derived from these curves are also given as a bar graph in Figs. 6b and 
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6c. SDTC and rheobase values of LEV, derived from these curves, were both found to be 
signifi cantly diff erent from those for CON (1.94 mA and 0.28 ms vs. 2.7 mA and 0.22 ms).
The threshold electroton us protocol aims to track the changes in excitability during 
and aft er the long-duration depolarization and hyperpolarization of sub-threshold current 
pulses. Threshold changes are plott ed as percent threshold reduction, so that depolarizing 
responses are plott ed upwards, which is more convenient for electrotonus. Mean threshold 
changes during and aft er the depolarization and hyperpolarization of sub-threshold current 
of 100 ms, corresponding to 40 and 20 % of maximal response (i.e., TEd40, TEd20 and TEh40, 
TEh20, resp., for depolarizing and hyperpolarizing currents) for CON and LEV groups, are 
Fig. 5. Stimulus response relationship for CON and LEV groups: a) curves and b) stimuli (mA) for 
50 % maximal response (mean ± SEM, n = 8, for both groups). Signifi cant diff erence vs. CON: *p < 0.05.
Fig. 6. a) Charge-duration relationship for CON and LEV groups; b) strength-duration time constant 
(SDTC); c) rheobase values calculated by line fi tt ing (mean±SEM, n=8 for both groups). Signifi cant 
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given in Fig. 7a. The percent threshold change curve of CON and LEV groups following 
depolarization revealed no signifi cant diff erence for either TEd40 or TEd20. Similarly, no sig-
nifi cant diff erence following hyperpolarization was found for either TEh40 or TEh20.
In the current threshold relationship, for an unconditioned test potential, the strength 
of the conditioning current is varied from +50 to –100 % of the threshold while keeping its 
duration constant. One can then obtain the curve for the current threshold relationship by 
delivering the test pulse of 1 ms duration at the end of polarizing current, corresponding 
to the rectifi cation due to K+ channels’ activation, i.e., the inward rectifi er. Current-thresh-
old relationships for depolarization and hyperpolarization for CON and LEV groups were 
found to be similar (Fig. 7b), without any signifi cant diff erence.
Recovery cycle (RC) properties, showing the relative refractory period, and providing 
information about super-excitability and late sub-excitability, are given in Fig. 8a for both 
CON and LEV. The RC curve for LEV was found to be shift ed to the right, meaning that 
the absolute refractory period for LEV had increased compared to CON (τ0 in Fig. 8a). The 
associated average relative refractory period values were found to increase signifi cantly 
for LEV (p < 0.05) compared to CON (Fig. 8b).
In vitro conduction studies
In the experiments conducted in vitro, isolated rat sciatic nerves manifested a charac-
teristic electrophysiological response to levobupivacaine (1.7 mmol L–1), i.e., a gradual 
CNAP depression with time. All responses to supramaximal stimuli were found to vanish 
within 25 min (Figs. 2 and 3). Despite the fact that there is a very limited number of in vitro 
nerve conduction studies in the literature, this complete blocking eff ect of levobupivacaine 
is consistent with a recent study reporting that the maximum eff ect of levobupivacaine (0.5 
mmol L–1) on the frog sciatic nerve CNAP amplitude occurred 20 minutes following expo-
sure (14). A similar response is reported in another study of motor and sensory functions 
Fig. 7. a) Threshold electrotonus; b) current threshold relationship for CON and LEVgroups (mean ± 
























Threshold reduction (%)Delay (ms)
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in an in vivo behavioral method, however, for a relatively higher dose than we used (15). 
Despite the diff erence in doses, considering the location and volume of injections, the 
impacts due to levobupivacaine could be considered to be the same.
The area of a CNAP waveform can be used as a measure of the number of activated 
nerve fi bers in the nerve trunk (16). The signifi cant area decrease (~42 %) observed in the 
5th minute following drug administration (Fig. 3a) can be interpreted as the block of fi ber 
groups having diff erent conduction velocities, based on our previous studies (17). Levobu-
pivacaine was also found to cause a signifi cant decrease (~56 %) in CNAP amplitude in the 
5th minute (Fig. 3b). Although the decrease is quite dramatic, amplitude change may not be 
a reliable measure of the duration of an anesthetic agent. Due to conduction velocity shift s 
between fi ber groups, there still seem to exist active fi bers conducting at a relatively lower 
velocity. It is known that the peak region of CNAP mainly consists of fi ber shaving a rela-
tively lower conduction velocity (18–20) than the fastest group. While the fast fi bers, i.e., 
having a larger diameter and lower threshold, contribute to the initial segment of CNAP, 
the fi bers having are latively slower conduction velocity, i.e., having a smaller diameter 
and high threshold, contribute to the tail section of the CNAP waveform (21, 22).
Conduction velocity changes calculated with respect to the on set (CVinit) and peak 
(CVpeak) instants of CNAP (Figs. 3c and 3d) confi rmed that there should still exist a certain 
amount of fi bers conducting in the 5th minute aft er levobupivacaine (0.05 %, 1.7 mmol L–1) 
administration. It is also apparent from Figs 3c and 3d that the signifi cant decrease of both 
CVinit and CVpeak starts in the 20th minute. Therefore, the time points at which the dra-
matic decrease occurs may be considered as a reliable measure for the maximum eff ect of 
levobupivacaine.
Fig. 8. a) Recovery cycle following the supramaximal conditioning stimulus curves on a logarithmic 
time-scale; b) average relative refractory period values for CON and LEV groups (mean ± SEM, n=8) 
for both groups). Signifi cant diff erence vs. CON: *p < 0.05. τ0, τ1, τ2, τ3 correspond to the absolute re-
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In vivo excitability studies
The time course of a drug eff ect is an important issue. In the conventional in vitro 
CNAP recording methods, there are two concerns that should be taken into account: the 
continuous action of levobupivacaine on the isolated nerve and the amount of impeding 
forces against diff usion. Therefore, we also tested the time point at which the maximal 
eff ect of levobupivacaine occurred by tracking the CMAP amplitude recorded from the 
gastrocnemius muscle. The CMAP results suggested the maximum eff ect to occur in the 
25th minute (data not shown), which is the same time point yielded by CNAP recordings. 
Therefore, this time point was chosen as the baseline for testing nerve excitability changes 
while applying the TT method.
Another fi nding from the TT method was the stimulus-response curve. As expected, 
it had a sigmoid shape for both CON and LEV groups (Fig. 5a). Although the stimulating 
current strength (mA) for 50 % maximal response was signifi cantly diff erent for CON and 
LEV (Fig. 5b and Table I, p < 0.05), the associated peak CMAP values (mV) were almost the 
same. This fi nding roughly refl ects the decrease in excitability due to LEV. However, a 
more detailed interpretation would be that levobupivacaine reduces the excitability of 
low-threshold fi bers, i.e., faster fi ber groups, due to the very fact that it is relatively harder 
to excite slower fi ber groups. Besides, it did not block conduction completely as it was the 
case of the isolated nerve.
Rheobase and chronaxie (SDTC) provide a conventional measure of nerve excitability 
and can be calculated using data from the CNAP recording method, which, however, re-
quires multiple recordings. The TT method, on the other hand, makes it possible to deter-
mine them easily, as shown by several experimental and clinical studies (5). The eff ects of 
levobupivacaine on rheobase and SDTC are given in Fig. 6 and Table I, where a negative 
correlation was found between the rheobase (Fig. 6c) and SDTC (Fig. 6b). Rheobase and 
SDTC are nodal properties infl uenced by the nodal membrane excitability. Their depen-
dence on the voltage level is consistent with persistent Na+ channels’ (Nap) behavior. Nap 
channels are active near the threshold and their inactivation is not as rapid as that of tran-
sient Na+ channels (6, 7, 23). Depolarization decreases due to the Na+ current through Nap, 
resulting in lower rheobase, whereas hyperpolarization has the opposite eff ect. As the 
charge-duration relationship suggests, SDTC takes values in the opposite direction from 
the rheobase (6). Hence, the membrane is prevented from hyperpolarizing due to leakage 
of Na+ through Nap channels, contributing to 3–5 % of the total Na+ channel activity during 
the resting state of the membrane.
A decrease in membrane potential or a change in passive membrane properties would 
cause a decrease in SDTC values. Since levobupivacaine decreases Na+ channels’ perme-
ability, the membrane should become hyperpolarized. This in turn leads to a decrease in 
SDTC, which is a strong evidence for a decrease in membrane excitability. This result sug-
gests that proper functioning of persistent Na+ channels in the rat sciatic nerve is restricted 
within 25 min aft er levobupivacaine injection, which may be responsible for decreased 
excitability.
Threshold electrotonus is another protocol enabling us to monitor the inter-nodal 
conductance, which in turn yields a characteristic patt ern of the change in excitability dur-
ing and aft er long-term depolarizing and hyperpolarizing currents unable to trigger an 
action potential. Under such conditions, the strength of the test pulse required to obtain 
305
S. Tuncer et al.: Axonal excitability and conduction alterations caused by levobupivacaine in rat, Acta Pharm. 67 (2017) 293–307.
 
the predetermined target CMAP amplitude is also changed relative to the pulse onset. In 
our study, target amplitudes were chosen to yield 20 and 40 % of CMAP maximum ampli-
tude. The rationale behind choosing two diff erent target response amplitudes is that the 
most excitable fi ber groups are the fastest ones and may result in 20 % target response, 
where the rest are the medium ones responsible for 40 % target response.
Threshold electrotonus curves revealed no diff erence for either TE d40 or TEd20. The 
patt erns followed by the TEh40 and TEh20 curves for both CON and LEV were almost the 
same (Fig. 7a). In the TEd40 curve, excitability remained almost the same over the fi rst 20 ms, 
with a slight decrease up to 100 ms. TEd20 curves of CON and LEV followed the same trend. 
These fi ndings are coherent with the TE (%) measures given in Table I. Since a change in 
nerve excitability during TEd is controlled successively by passive membrane properties 
(i.e., resistance and capacitance) and also via fast and slow K+ channel conductance (5, 6), 
the threshold electrotonus fi ndings can be interpreted in such a way that levobupivacaine 
has no signifi cant eff ect on the passive membrane properties and on K+ conductance for 
either fastest or medium velocity fi ber groups. Besides, the current-threshold curves for 
both groups were also found to follow the same trend (Fig. 7b). These results support our 
suggestion of a limited eff ect of levobupivacaine on K+ channels, since hyperpolarization 
deactivates inter-nodal K+ channels while activating the inward rectifi er K+ channels (5).
The sequence of change in excitability, following nerve fi ber depolarization, is called 
the recovery cycle, which can be either in an increasing (i.e., below baseline) or decreasing 
phase (i.e., above baseline). These phases are labeled in Fig. 8a as τ0, τ1, τ2, and τ3 for the 
CON group. There was a complete rightward shift  in the average curve of LEV groups, 
compared to CON groups, meaning that levobupivacaine infl uenced the inactivation and 
deactivation phases of ion channels. Increase in phase τ0 (absolute refractory period) of the 
LEV group shows that even when the strongest stimuli are applied, the fi bers are abso-
lutely unexcitable. This prolongation in τ0 is due to the delay in inactivation of the transient 
voltage dependent Na+ channels. In phase τ1 (relative refractory period), axonal excitabil-
ity in the LEV group is low, and there is also a signifi cant (p < 0.05) extension in duration 
(Fig. 8b) that may be att ributed to the delay caused by levobupivacaine as it causes gradu-
al recovery of transient Na+ channels. Axonal excitability increases during phase τ2 (super-
normal period). Compared to the CON group, there is a substantial rightward shift  in the 
LEV group, and its duration is longer. Finally, for phase τ3, the LEV group either vanishes 
completely or phase τ2 (supernormal period) is delayed towards τ3 as a result of complete 
shift .
CONCLUSIONS
The current study was designed to investigate, using two well-established methods, 
how the long-acting amide type local anesthetic levobupivacaine aff ects nerve conduction 
and excitability parameters.
Conventional methods based on the compound nerve action potential recording still 
keep their place in investigating the state of conduction and fi ber diameter distribution in 
peripheral nerve studies. As it was pointed out before, the time course of the eff ect of an 
administered anesthetic drug may be traced precisely by this method. The method also 
facilitates the estimation of conduction velocity shift s in fi ber groups and the excitability 
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state of the nerve trunk. Various protocols of the TT method, however, make in vivo inves-
tigation of channel kinetics possible, even in humans. 
Consequently, this study was aimed to investigate the electrophysiological parame-
ters upon administration of levobupivacaine on isolated sciatic nerves for some time. This 
study employed an automated TT system to investigate multiple excitability parameters of 
the rat sciatic nerve, which corresponds to the maximum response following peri-neural 
injection of levobupivacaine. 
Finally, the study has demonstrated that levobupivacaine (0.05 %, 1.7 mmol L–1) de-
presses conduction in the isolated sciatic nerve in a time-dependent manner, and that 
complete conduction block occurs 20 minutes aft er administration. Levobupivacaine 
causes a decrease in Na+ channel activity (or permeability), with an increase in the rheo-
base and in absolute/relative refractory periods and a decrease of SDTC values, as revealed 
by the in vivo TT method results. Changes in the assessed parameters could be accepted 
asevidencefor the decrease in the excitability state of nerve fi bers in response to levobupi-
vacaine application.
Acronyms, symbols. – AMPA – α-amino-3-hydroxy-5-methyl-4-izoxazolepropionic acid; ARRIVE 
– Animal research: Reporting of in vivo experiments; CMAP – compound muscle action potential; 
CNAP – compound nerve action potential; CVinit – conduction velocity derived using latency1; CVpeak 
– conduction velocity derived using latency 2; GTP – guanosine triphosphate; KONUDAM – N. E. 
University Experimental Medicine and Application Center; KSPS – kilosamples s–1; NMDA – N-meth-
yl-D-aspartate; Nap – persistent Na+ channels; QTRACS – soft ware for applying multiple excitability 
protocol; QTRACP – soft ware for analyzing multiple excitability data; RETICAP – open-source com-
pound nerve action potential recording soft ware; RC – recovery cycle; SDTC – strength-duration time 
constant; Δtonset – latency1, time delay between the instant of stimulus delivery and the associated 
CNAP onset; Δtpeak – latency2, time delay between the stimulus delivery instant and the associated 
CNAP reaching its maximum value; TE – threshold electrotonus; TEd40 – depolarizing sub-threshold 
current for 40 % of maximal response; TEd20 – depolarizing sub-threshold current for 20 % of maxi-
mal response; TEh40 – hyperpolarizing sub-threshold current for 40 % of maximal response; TEh20 
– hyperpolarizing sub-threshold current for 20 % of maximal response; TRONDNF – multiple excit-
ability protocol; TRPV1 – transient receptor potential vanilloid 1; TT – threshold tracking
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